'Major breakthrough' for deadly skin cancer treatment

Los Angeles Times, June 6, 2011

Two new drugs can significantly increase survival in patients with metastatic melanoma, the advanced and generally lethal form of skin cancer, researchers reported. Results were so dramatic in a trial of one of the drugs that the study was halted early, researchers reported Sunday at a Chicago meeting of the American Society of Clinical Oncology. Studies on both drugs were published online by the New England Journal of Medicine. Melanoma is among the most common cancers in the United States. An estimated 68,000 new cases are diagnosed each year, with 8,700 deaths. The shortened trial is notable because the experimental agent called PLX4032, or vemurafenib, is the first chemotherapy agent directed at a specific mutation involved in the formation of skin tumors.


MOST POPULAR

" style="font-family:inherit">Physician's Scathing Remarks Humiliate Patient, Cost Hospital
  • Alternative Staffing Arrangements
  • " style="font-family:inherit">The Perils of Cut-and-Paste Documentation
  • Aging Doctors: Time for Mandatory Competency Testing?
  • 7 Years In, Triple Aim Transcends Jargon
  • Alternative Staffing Arrangements
  • CMS Predictive Readmission Models 'Not Very Good'
  • SPONSORED REPORTS
    SPONSORED HEADLINES

    SIGN UP

    FREE e-Newsletters Join the Council Subscribe to HL magazine

    SPONSORSHIP & ADVERTISING

    100 Winners Circle Suite 300
    Brentwood, TN 37027

    800-727-5257

    About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
    © HealthLeaders Media 2014 a division of BLR All rights reserved.